Tolterodine Tartrate Patent Expiration
Tolterodine Tartrate was first introduced by Upjohn Us 2 Llc
Tolterodine Tartrate Patents
Given below is the list of patents protecting Tolterodine Tartrate, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Detrol La |
US6630162 (Pediatric) | Pharmaceutical formulation and its use |
May 11, 2020
(Expired) | Upjohn |
| Detrol La |
US6911217 (Pediatric) | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
May 11, 2020
(Expired) | Upjohn |
| Detrol La |
US6770295 (Pediatric) | Therapeutic formulation for administering tolterodine with controlled release |
Feb 26, 2020
(Expired) | Upjohn |
| Detrol La | US6630162 | Pharmaceutical formulation and its use |
Nov 11, 2019
(Expired) | Upjohn |
| Detrol La | US6911217 | Controlled release bead, a method of producing the same and multiple unit formulation comprising it |
Nov 11, 2019
(Expired) | Upjohn |
| Detrol La | US6770295 | Therapeutic formulation for administering tolterodine with controlled release |
Aug 26, 2019
(Expired) | Upjohn |
| Detrol |
US5382600 (Pediatric) | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep 25, 2012
(Expired) | Upjohn |
| Detrol La |
US5382600 (Pediatric) | 3,3-diphenylpropylamines and pharmaceutical compositions thereof |
Sep 25, 2012
(Expired) | Upjohn |
Tolterodine Tartrate's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Tolterodine Tartrate:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Non-invasive Saphenous Nerve Stimulation Therapy for Overactive Bladder | NinaMED Pty Ltd | NA |
NOT YET RECRUITING
(Jul 1, 2026)
| PHASE3 |